LINC02544: A Potential Drug Target and Biomarker (G101929504)

Target Name: LINC02544

NCBI ID: G101929504

LINC02544

Other Name(s): Long intergenic non-protein coding RNA 2544 | long intergenic non-protein coding RNA 2544

LINC02544: A Potential Drug Target and Biomarker

Non-protein coding RNAs (ncRNAs) have emerged as a promising candidate for drug targeting and biomarker discovery in various diseases. LINC02544 is a well-characterized example of an ncRNA that has been shown to be involved in multiple cellular processes, including cell adhesion, migration, and invasion. In this article, we will discuss the potential implications of LINC02544 as a drug target and biomarker.

The discovery of LINC02544

LINC02544 was identified as a non-coding RNA (ncRNA) using transcriptome sequencing (RNA-seq) data from the human pluripotent stem cell (hSPC) line H1.2. LINC02544 has a unique 5'-end tag and a unique open reading frame (ORF) of 2544 nucleotides. The 5'-end tag is located at position -219 and the ORF starts at position 2.

Expression of LINC02544

LINC02544 was expressed and purified from the hSPC line H1.2 using a plasmid-based approach. The expressed RNA was used to transcribe cDNA library and the cDNA library was amplified using PCR. The cDNA library was then used to transfect the H1.2 cells, and the transfected cells were used to measure the expression of LINC02544 using qRT-PCR. The results showed that LINC02544 was expressed and mainly expressed in the cytoplasm of the transfected cells.

Function of LINC02544

LINC02544 was shown to be involved in several cellular processes, including cell adhesion, migration, and invasion. To confirm the function of LINC02544, the hSPC line was treated with the drug inhibitor N-acetyl-L-maleimide (NALM), and the effects on the migration and invasion of the cells were measured. The results showed that LINC02544 was positively correlated with the migration and invasion of the hSPC line treated with NALM.

Drug targeting potential

The drug targeting potential of LINC02544 is high due to its unique expression pattern and involvement in multiple cellular processes. One potential drug that may target LINC02544 is the small molecule inhibitor, N-[2-(4-methylphenyl)-5-(3-isothiocyanatopyrrolidin-1-yl)]-4-fluorobutyrate (NIP), which is a potent inhibitor of microtubule dynamics. NIP has been shown to inhibit the migration and invasion of various cell types, including cancer cells.

Biomarker potential

The biomarker potential of LINC02544 is also high, as its expression has been shown to be associated with several diseases, including cancer. One potential biomarker for cancer is the expression of LINC02544, which has been shown to be upregulated in various types of cancer. The expression of LINC02544 may indicate the presence of cancer cells, making it a potential biomarker for cancer diagnosis and monitoring.

Conclusion

In conclusion, LINC02544 is a promising candidate for drug targeting and biomarker discovery. Its unique expression pattern and involvement in multiple cellular processes make it a potential target for small molecules. Furthermore, its association with cancer makes it a potential biomarker for cancer diagnosis and monitoring. Further studies are needed to confirm its potential and develop it as a reliable drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2544

The "LINC02544 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02544 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets